Drugmakers including Merck & Co (MRK.N), AstraZeneca Plc (AZN.L) and AbbVie Inc (ABBV.N) said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry’s larger players look for new sources of future revenue. Several top drugs such as AbbVie flagship Humira have begun to face competition from new rivals or are expected to lose patent protections in the next few years, and deals could be a quick fix to address the loss of revenue from older therapies.
Read the full article: Drugmakers Scout for Deals, Ramp up Research Spending //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/wrapup-drugmakers-post-healthy-results-growth-drivers-shine-2023-04-27